Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PRF TechnologiesPRFX -2.38%22 EV-to-EBITDA is 1.76 as of Sep. 09, 2026, which is 259% above its 10-year median of 0.49. GuruFocus rates PRFX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 726 Drug Manufacturers companies, PRF Technologies ranks better than 95.32% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PRF Technologies's enterprise value is $-7.62 Mil.
PRF Technologies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-4.32 Mil. Therefore, PRF Technologies's EV-to-EBITDA for today is 1.76.
The historical rank and industry rank for PRF Technologies's EV-to-EBITDA or its related term are showing as below:
PRFX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.07 Med: 0.49 Max: 1.76
Current: 1.76
During the past 8 years, the highest EV-to-EBITDA of PRF Technologies was 1.76. The lowest was -0.07. And the median was 0.49.
PRFX's EV-to-EBITDA is ranked better than 95.32% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.4
vs PRFX: 1.76
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PRF Technologies's PE Ratio (TTM) for today is calculated as:
PRF Technologies's share price for today is $0.9324.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PRF Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-5.508.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PRF Technologies's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PRF Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PRF Technologies EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PRF Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PRF Technologies's EV-to-EBITDA falls into.
PRF Technologies's current Enterprise Value is $-7.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PRF Technologies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-4.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PRF Technologies (PRFX) has a EV-to-EBITDA of 1.76 as of Sep. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PRF Technologies. This is 259% above median its historical median of 0.49. According to the industry distribution chart, PRF Technologies ranks #34 out of 726 companies in the Drug Manufacturers industry, placing it in the top 4.7%.
Is PRF Technologies' EV-to-EBITDA too high?
PRF Technologies' current EV-to-EBITDA of 1.76 is 259% above median its 10-year median of 0.49. The Drug Manufacturers industry median EV-to-EBITDA is 13.40. PRF Technologies' value of 1.76 is 86.9% below this industry median. Based on the distribution chart, PRF Technologies ranks #34 out of 726 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PRF Technologies has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does PRF Technologies' EV-to-EBITDA compare to CTTH and UPC?
According to the Drug Manufacturers industry distribution chart, PRF Technologies ranks #34 out of 726 companies for EV-to-EBITDA. This places PRF Technologies in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.40. PRF Technologies' value of 1.76 is 86.9% below this benchmark. While the company's 10-year median is 0.49 vs. the industry median of 13.40, PRF Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.40, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PRF Technologies's current EV-to-EBITDA of 1.76 is 86.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PRF Technologies. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PRF Technologies's current EV-to-EBITDA is 1.76, which is 259% above median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PRF Technologies stock overvalued right now?
PRF Technologies (PRFX) has a current EV-to-EBITDA of 1.76. The current EV-to-EBITDA is 1.76, which is 259% above median its 10-year median of 0.49 and 86.9% below the Drug Manufacturers industry median of 13.40. PRF Technologies' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PRF Technologies (PRFX), the current EV-to-EBITDA is 1.76 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
22GF Score
Get the complete analysis for PRFX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRFX has been successfully added to your 
